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Abstract: The association between functional β2 adrenergic receptor (β2-AR) polymorphisms and cardiac autonomic 
modulation is still unclear. Thus, two common polymorphisms in the β2-AR gene (Gln27Glu β2 and Arg16Gly β2) were 
studied to determine whether they might affect tonic and reflex cardiac sympathetic activity in healthy young sub-
jects. A total of 213 healthy young white subjects of both genders (53% female), aged 18-30 years (23.5±3.4 y), had 
their continuous blood pressure curves noninvasively recorded by Finometer at baseline, and other hemodynamic 
parameters, as cardiac autonomic modulation, baroreflex sensitivity, and allele, genotype, and diplotype frequen-
cies calculated. Associations were made between Arg16Gly β2 and Gln27Glu β2 polymorphisms and between β2-AR 
diplotypes and all variables. The heart rate was significantly lower (P<0.001) in the presence of homozygous Arg/
Arg alleles (60.9±1.5 bpm) than in that of Arg/Gly heterozygotes (65.9±1.0 bpm) or Gly/Gly homozygotes (66.3±1.2 
bpm). Homozygous carriers of Arg16 allele had an alpha index (19.2±1.3) significantly higher (P<0.001) than that 
of the subjects with the Gly allele Gly/Gly (14.5±0.7) or Arg/Gly (14.6±0.7). Furthermore, the recessive Glu27Glu 
and the heterozygous Gln27Glu genotypes had a higher percentage of low-frequency components (LF%) than the 
homozygous Gln27Gln (15.1% vs. 16.0% vs. 8.2%, P=0.03, respectively). In healthy young subjects, the presence of 
β2-AR Arg16 allele in a recessive model was associated with higher baroreflex sensitivity, and increased parasympa-
thetic modulation in studied individuals. 
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Introduction
β1 and β2 adrenergic receptors (β1- and β2-ARs) 
have a pivotal role in the sympathetic nervous 
system, which controls various physiological 
functions, including energy homeostasis, glu-
cose and lipid metabolism as well as cardiovas-
cular (CV) moment-to-moment regulation [1]. 
Single nucleotide polymorphisms have been 
described in the gene encoding human β2-AR, 
and they can affect the function of the receptor 
in vitro [2]. Functional and common human 
Arg16Gly and Gln27Glu β2-AR polymorphisms 
have been examined for association with hyper-
tension, [3] obesity [4, 5], type 2 diabetes [6], 
and sudden death [7]. The studies reach con-
flicting results since the great many factors 
under consideration, including the complexities 
of the phenotypes and the age of the study 
sample, may easily confound the researchers 
and thus hinder data interpretation. The func-
tional relevance of Arg16Gly and Gln27Glu 
β2-AR polymorphisms has been studied mainly 
in 2 pathways: heart rate (HR) and vasodilators 
responses. Many studies indicate that, in 
healthy subjects, HR has only marginal geno-
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type-dependent effects on Arg16Gly and Gln- 
27Glu β2-AR polymorphisms [8].
Methods of higher sensitivity such as time 
domain and spectral analyses of HR variability 
[9] could be used to dissect the association 
between cardiac modulation and Arg16Gly and 
Gln27Glu β2-AR polymorphisms since they 
reflect the sympathetic (adrenergic receptors) 
and parasympathetic (muscarinic receptors) 
nerve activity over the sinoatrial node [10, 11].
Furthermore, the baroreflex, the most impor-
tant autonomic mechanism controlling CV func-
tion, may also be affected by β2-AR gene varia-
tion. In fact, decreased baroreflex sensitivity is 
associated with increased sympathetic activity 
and higher cardiovascular (CV) morbidity and 
mortality [12]. 
In a published study conducted with young 
Japanese male subjects, homozygous carriers 
of the β2-AR Arg16 allele had lower sympathetic 
activity than subjects with the Gly allele, and 
carriers of β2-AR Glu27 allele were linked with 
higher cardiac sympathetic autonomic activity 
[13]. However, given the significant differences 
in genetic profile of different racial/ethnic 
groups, we carried out a study to test the 
hypothesis that Arg16Gly and Gln27Glu β2-AR 
polymorphisms influence functional physiologi-
cal characteristics, such as HR, cardiac sympa-
thetic modulation, and CV reflex control, which 
are considered intermediate phenotypes with 
profound implications for the development of 
CV disease. We studied the correlation of 
Arg16Gly and Gln27Glu β2-AR polymorphisms 
with hemodynamic parameters, norepineph-
rine levels, cardiac autonomic modulation, and 
Table 1. Baseline characteristics and genotype distribution according to gender in 213 apparently 
healthy young subjects
Variables Women (n=113) Men (n=110) Total (n=213) P-value
Age (years)  23.4 (±3.7) 23.7 (±3.4) 23.5 (±3.4) 0.32
Body mass index (kg/m2) 22.2 (±3.4) 24.5 (±3.8) 23.3 (±3.8) <0.0001
AC *(cm) 72.8 (±8.6) 82.0 (±9.9) 77.2 (±10) <0.0001
Current Smoking (%) 8 (7.0) 9 (9.0) 17 (8.0) 0.61
SBP (mmHg) 112.4 (±8.1) 116.5 (±8.5) 114.3 (± 8.5) 0.002
DBP (mmHg) 70.5 (±6.2) 73.4 (7.4) 71.9 (±6.9) <0.0001
Total cholesterol (mg/dl) 175.6 (±31) 159.4 (±37) 167.9 (±35.3) 0.008
LDL-C cholesterol (mg/dl) 92.8 (±26.2) 91.2 (±32.7) 92 (±29.4) 0.80
HDL-C cholesterol (mg/dl) 65.4 (±14) 51.4 (±10) 58.7 (±14.6) <0.0001
Triglycerides (mg/dl) 87.2 (±36) 84.2 (±46) 85.8 (±41.6) 0.70
Insuline levels (mUIml) 7.7 (±3.4) 7.5 (±10.5) 7.7 (±7.5) 0.90
Fasting glucose (mG/dl) 83.5 (±7.8) 84.4 (±7.7) 85.4 (±7.9) 0.004
Creatinine (mg/dl) 0.77 (±0.1) 0.98 (±0.1) 0.9 (±0.2) <0.0001
Hemoglobin (%) 40.2 (±0.8) 45.6 (±2.7) 42.7 (±3.7) <0.0001
Hematocrit (g/dl) 13.4 (±0.8) 15.4 (±1.0) 14.4 (±1.4) <0.0001
Genotype distribution
Gln27Glu 0.80
    Gln/Gln 59 (52.2) 47 (47.0) 106 (49.8)
    Gln/Glu 41 (36.3) 47 (47.0) 88 (41.3)
    Glu/Glu 13 (11.5) 6 (6.0) 19 (8.9)
Arg16Gly 0.17
    Gly/Gly 38 (33.6) 33 (33.0) 71 (33.0)
    Arg/Gly 50 (44.2) 41 (41.0) 91 (42.7)
    Arg/Arg 25 (22.1) 26 (26.0) 51 (23.9)
For baseline characteristics, values are expressed as mean ± standard deviation (± SD). For genotype distributions, values are 
expressed as frequency and percentage. AC *=abdominal circumference. All the polymorphisms tested were in Hardy-Weinberg 
equilibrium (p>0.05). Some proportions might not add up to 100% due rounding.
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baroreflex sensitivity in healthy young male and 
female Brazilian subjects. 
Methods
Studied population
A total of 213 white young subjects of both gen-
ders (53% female), aged 18-30 years (mean ± 
SE: 23.5±3.4), were included in the protocol. All 
subjects underwent a careful clinical examina-
tion and had their blood pressure (BP) and 
anthropometric measurements, such as height, 
weight, body index mass (BMI), and abdominal 
circumference (AC), recorded. All subjects were 
classified as normotensive according to current 
guidelines (office BP <140/90 mmHg) and were 
nonobese (BMI <30 Kg/m2). Information about 
their health conditions, habits, use of medica-
tion, and family history was obtained through 
interviews. Additionally, all subjects took labo-
ratory tests to verify their metabolic status (tri-
glycerides, insulin, total cholesterol, LDL-chole- 
sterol, HDL-cholesterol and glucose levels, and 
red blood cell count). The exclusion criteria 
were any chronic diseases, pregnancy, and reg-
ular use of any medication (except oral contra-
ceptives). The study protocol was reviewed and 
approved by the appropriate institutional review 
committees, the Human Subject Protection 
Committees of the Heart Institute (InCor) and 
the Clinic Hospital, University of São Paulo, and 
was conducted in accordance with World 
Medical Association International Code of 
Medical Ethics (Declaration of Helsinki, 1964; 
revised in 2008). Subjects were informed about 
to be re-genotyped by two independent tech- 
nicians. 
Experimental protocol
The experimental protocol was always per-
formed in the morning in a quiet room with tem-
perature control (22°C). Subjects were asked 
to abstain from alcohol, tobacco, intense exer-
cise and sleep deprivation 24 h before the 
study, and water intake was stimulated. Each 
patient rested supine was monitored with an 
electrocardiogram (ECG) machine, a noninva-
sive beat-by-beat arterial blood pressure 
device, and an abdominal impedance plethys-
mography belt (pneumograph). A venous punc-
ture was also performed. 
Continuous BP waveforms were obtained by a 
digital photoplethysmograph device (Finome- 
ter®, Finapres Medical System BV, Holland). A 
software program (BeatScope) used BP curves 
and patient data (age, sex, weight, and height) 
to calculate systolic and diastolic BP (SBP and 
DBP), HR, cardiac output (CO), and peripheral 
vascular resistance (PVR). The waveforms were 
simultaneously recorded on another computer 
equipped for acquisition and conversion of the 
biological signals AT/MCA-CODAS (DATAC 
Instruments Inc., Akron, Ohio, USA). The sam-
pling frequency of signals was 1000 Hz. The 
stored data underwent a routine analysis to 
provide HR and BP variability. 
The procedures for power spectral analysis of 
R-R interval (heart rate variability-HRV) and 







HR (bpm) 66.3 (±1.2) 65.9 (±1.0) 60.9 (±1.5)# <0.0001
SBP (mmHg) 119.1 (±1.1) 120.7(±1.1) 118.9 (±1.2) 0.47
DBP (mmHg) 68.1 (±0.6) 69.0(±0.6) 67.1 (±0.9) 0.16
MBP (mmHg) 87.5 (±0.8) 88.6 (±0.7) 86.4 (±1.1) 0.18
CO (l/minutes) 5.7 (±0.2) 5.8 (±0.1) 5.6 (±0.2) 0.63
TPR (mmHg. s/mL) 0.96 (±0.02) 0.94 (±0.01) 1.0 (±0.03) 0.70
Nor (pg/mL) 70.7 (±5.1) 78.8 (±6.7) 71.6 (±7.1) 0.59
Values are mean and standard deviation (± SD). P-values=comparison among 
groups. HR=Heart Rate; SBP=Systolic Blood Pressure; DBP=Diastolic Blood Pres-
sure; CO=Cardiac Output; TPR=Total Peripheral Resistance; Nor=Norepinephrine. 
Some proportions might not Cadd up to 100% due rounding. #=p<0.05 Arg/Arg 
group vs. Arg/Gly and Gly/Gly groups.
the research protocol and a 
written informed consent was 
obtained from each study sub- 
ject. 
Genotyping protocol
Briefly, genomic DNA was extra- 
cted from leukocytes in whole 
blood samples after a standard 
salting-out technique [14]. Ge- 
notypes were detected by poly-
merase chain reaction (PCR) 
followed by restriction fragment 
length polymorphism (RFLP) 
analysis [15]. Quality control for 
these assays was carried out by 
randomly selecting 60 samples 
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blood pressure variability (BPV) have been 
described in the literature. Each heart beat was 
identified using a specialized algorithm that 
was implemented for Matlab MT (MATLAB 6.0, 
Mathworks, USA) and that makes the automat-
ic detection of systolic and diastolic pressure 
wave events. Pulse interval (PI) or R-R interval 
was calculated as the difference between the 
beginning and end points of the cycle (t1-t0). The 
power spectral density of the R-R interval and 
systolic blood pressure were computed using 
the Fast Fourier Transform and Welch’s method 
over 16,384 points with a Hanning window and 
50% overlapping. Spectral bands evaluated for 
humans were defined according to literature 
references: very low-frequency (VLF; 0.007-
0.04 Hz), low frequency (LF; 0.04-0.15 Hz), high 
frequency (HF; 0.15-0.4 Hz), and total power 
[9]. Baroreflex sensitivity was also inferred from 
the alpha index (ratio of R-R LF ms2/BP LF 
mmHg2) [16].
A peripheral venous blood sample was collect-
ed for the measurement of plasma norepineph-
rine concentration (measured by high-perfor-
mance liquid chromatography at the Nephrology 
Laboratory, University of São Paulo) [17] with 
the patient in supine position. 
Statistical analysis
First, a distribution of continuous variables was 
constructed with the medians (interquartile 
range) or means (± SD) of the baseline charac-
teristics. Absolute and relative frequencies 
were estimated for categorical variables. 
Alleles, genotype and diplotype frequencies 
were calculated and the Hardy-Weinberg equi-
librium test using χ2-analyses was applied. Pair- 
for means of continuous variables. A two-tailed 
P-value of 0.05 was considered significant. 
Statistical analyses were made with the SAS 
version 9.1 and with the SPSS version 16.0. 
Data were expressed as ± SEM.
Results
Characteristics of the studied subjects
Table 1 shows baseline characteristics and 
genotype distribution in 213 healthy young sub-
jects according to gender. All parameters were 
within the reference range for age. In a gender-
stratified analysis, we found that men (n=100) 
had higher body mass index (BMI), abdominal 
circumference (AC), systolic (SBP) and diastolic 
blood pressure (DBP), fasting glucose, serum 
creatinine, hemoglobin, and hematocrit values 
than women (n=113), while women had a high-
er HDL-cholesterol level as compared with men. 
In the entire study sample (n=213), allele and 
genotype frequencies of both Arg16Gly and 
Gln27Glu genotypes (Table 1) were concordant 
with the Hardy-Weinberg equilibrium (P>0.05). 
At Codon 16, the allele frequency of Gly was 
70.3% and that of Arg was 29.7%; at Codon27, 
the frequencies of Gln and Glu were 54.3% and 
45.7%, respectively. The genotype frequencies 
of Gly16Gly, Arg16Gly, and Arg16Arg were 
49.8%, 41.1%, and 9.1%, respectively. The fre-
quencies of Gln27Glu, Gln27Gln, and Glu27Glu 
were 32.5%, 43.7%, and 23.9%, respectively. It 
is worth noting that we did not find any male-
female differences in genotype frequencies 
(Table 1). Overall, polymorphisms were in mod-
est linkage disequilibrium with one another 
(normalized Lewontin’s D’=0.72). 







HR (bpm) 64.6 (±1.0) 64.7 (±1.1) 65.8 (±2.8) 0.9
SBP (mmHg) 119.5 (±1.0) 119.9 (±1.0) 120.5 (±1.7) 0.89
DBP (mmHg) 68.2 (±0.6) 68.4 (±0.7) 67.5 (±1.1) 0.84
MBP (mmHg) 87.6 (±0.7) 87.8 (±0.8) 87.1 (±1.3) 0.95
CO (l/minutes) 5.7 (±0.1) 5.9 (±0.1) 5.3 (±0.2) 0.22
TPR (mmHg.s/mL) 1.0 (±0.02) 0.9 (±0.02) 1.0 (±0.04) 0.18
Nor (pg/mL) 76.1 (±6.1) 75.1 (±4.8) 61.1 (±10.1) 0.55
Values are mean and standard deviation (± SD). P-values=comparison among 
groups. HR=Heart Rate; SBP=Systolic Blood Pressure; DBP=Diastolic Blood Pres-
sure; CO=Cardiac Output; TPR=Total Peripheral Resistance; Nor=Norepinephrine. 
Some proportions might not add up to 100% due rounding.
wise linkage disequilibrium (LD) 
was examined as described by 
Devlin and Risch. Next, an analy-
sis was made of the association 
between β2-AR genotypes and 
demographic, anthropometric, 
and laboratory data, cardiac 
autonomic balance (HR variabil-
ity, SBP and DBP, CO, total 
peripheral resistance, and nor-
epinephrine levels), and hemo-
dynamic parameters.
Chi-square was used to test the 
association between categorical 
variables, while ANOVA and the 
Bonferroni posttest were used 
Arg16Gly and Gln27Glu β2 adrenergic polymorphisms in young Brazilians
157 Am J Transl Res 2015;7(1):153-161
Association of β2 gene polymorphisms with 
hemodynamic parameters, autonomic modula-
tion, and baroreflex sensitivity
Association of heart rate, BP, cardiac output, 
total peripheral resistance values, and norepi-
nephrine levels of all of the study subjects with 
Arg16Gly and Gln27Glu genotypes are dis-
played in Tables 2 and 3, respectively. 
Examination of Arg16Gly genotypes shows the 
heart rate was significantly lower (P<0.001) in 
the presence of homozygote Arg/Arg alleles 
(60.9±1.5 bpm) than in that of heterozygote 
Arg/Gly (65.9±1.0 bpm) or homozygote Gly/Gly 
(66.3±1.2 bpm) (Table 2). Other hemodynamic 
parameters, as well as norepinephrine levels, 
were similar across Arg16Gly genotypes at 
baseline. No significant differences were dete- 
cted in hemodynamic and norepinephrine lev-
els at baseline across Gln27Glu genotypes, as 
observed in Table 3. 
Analysis of HRV and BPV were evaluated in time 
and frequency domain. The evaluation of 
Arg16Gly genotypes shows that SDNN index 
was increased in Arg/Arg (SDNN=78±3 ms) 
alleles as compared with heterozygote Arg/Gly 
(SDNN=67±3 ms) (Figure 1). RMSSD and 
pNN50 were higher in the presence of homozy-
gote Arg/Arg alleles (rMSSD=80±6 ms; pNN- 
50=46±3%) than homozygote Gly/Gly (rMS- 
SD=50±3 ms; pNN50=37±2%) and heterozy-
gote Arg/Gly (rMSSD=59±5 ms; pNN50= 
30±3%) (Figure 1). As observed in Figure 2, 
heart rate variability in time domain was not dif-
feret between Gln27Glu genotypes subjects.
Figure 1. Heart rate variability in time domain stratified per Arg16Gly genotypes. Values are mean and standard de-
viation (± SD). P-values=comparison among groups. *=p<0.05 Arg/Arg group vs. Arg/Gly; #=p<0.05 Arg/Arg group 
vs. Arg/Gly and Gly/Gly groups.
Figure 2. Heart rate variability in time domain stratified per Gln27Glu genotypes. Values are mean and standard 
deviation (± SD). P-values=comparison among groups.
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The Var RR and absolute LF component of HRV 
were similar among the studied Arg16Gly geno-
types (Table 4). The absolute HF component of 
HRV was higher in homozygote Arg/Arg than 
homozygote Gly/Gly; and similar between 
homozygote Gly/Gly and heterozygote Arg/Gly. 
The LF%, HF% components of HRV, and the LF/
HF ratio reveal that Arg16Gly polymorphisms 
had a similar cardiac autonomic modulation at 
baseline (Table 4). 
The Var SBP and absolute LF component of 
SBP were similar among the groups. However, 
homozygous carriers of Arg16 allele had a high-
er alpha index than in subjects with the Gly 
allele (Table 4).
The parameters of HRV and BPV in the time and 
frequency domains, stratified per Gln27Glu 
genotypes (Gln/Gln, Gln/Glu and Glu/Glu), were 
similar among studied groups (Table 5).
Discussion
The main findings of the present study suggest 
that healthy young white Brazilian subjects, 
who were homozygous for the β2-AR Arg16 
allele, presented a lower resting HR, higher 
vagal modulation, and higher baroreflex sensi-
tivity than carriers of the Gly16 allele. However, 
it was not observed in Gln27Glu genotypes. 
These data thus indicate that, in a healthy 
young population, the β2-AR Gly16Arg polymor-
phisms can influence intermediate phenotypes, 
such as HR, cardiac parasympathetic modula-
tion, and baroreflex sensitivity. These results 
are important because such intermediate phys-
other morbidities that increase CV risk like dia-
betes mellitus. In addition, a decrease in baro-
reflex sensitivity is also an independent predic-
tor of CV events [12].
In the present study, subjects with the β2-AR 
Arg16 allele had protective intermediate traits 
characterized by increased cardiac parasympa-
thetic modulation and higher baroreflex sensi-
tivity than carriers of the Gly16 allele. We did 
not detect differences among groups concern-
ing blood pressure and cardiac output at rest. 
Previous studies have demonstrated an asso-
ciation of Gly16 allele with elevated blood pres-
sure [21, 22] and plasma norepinephrine than 
Arg16 carriers [23]. Differences in population 
[21, 22] or in experimental conditions [23] may 
have influenced the discrepancy in the results. 
β2-AR Gly16Arg and Gln27Glu polymorphisms 
are localized in the extracellular amino-termi-
nus region of the protein, and in vitro studies 
have indicated that they have a subtle effect on 
the agonist-promoted down regulation of the 
receptor expression when studied in a cell-
based system where transfections of vectors 
containing only the open reading frames [24]. 
The in vitro impact of β2-AR gene polymor-
phisms has been extensively reviewed [25]. 
Taken together, the results of different studies 
it has been demonstrated that the β2-AR 
Gly16Arg genotypes appear to influence the 
degree of agonist-induced receptor desensiti-
zation [26], with Gly16 showing increased ago-
nist-induced desensitization compared with 
Arg16 [24]. On the other hand, the presence of 
Glu27, rather than Gln27, is associated with 
resistance to desensitization [26].







Var RR 4876 (±423) 5479 (±563) 6884 (±896) 0.10
LF (ms2) 1346 (±132) 1679 (±155) 1856 (±176) 0.09
HF (ms2) 1432 (±132) 1721 (±87) 1899 (±132)† <0.05
LF (%) 49 (±3.4) 49 (±4.1) 49 (±3.9) 0.99
HF (%) 51 (±3.4) 50 (±4.1) 51 (±3.9) 0.99
LF/HF 0.94 (±0.11) 1 (±0.1) 1 (±0.1) 0.89
Var SBP 53 (±3) 47 (±4) 50 (±10) 0.45
LF (mmHg2) 6 (±1.0) 8 (±1.2) 5 (±0.8) 0.15
α index (ms/mmHg) 15 (±0.6) 14 (±0.7) 19.26 (±1)# <0.05
Values are mean and standard deviation (± SD). P-values=comparison among groups. 
†=p<0.05 Arg/Arg group vs. Gly/Gly group; #=p<0.05 Arg/Arg group vs. Arg/Gly and 
Gly/Gly groups.
iological traits in healthy indi-
viduals may be predictive of 
future disease or a distant 
phenotype [18]. Furthermore, 
to our knowledge, this is the 
first study conducted in 
Brazilian health population. 
Resting HR has been shown 
to be positively correlated 
with subsequent develop-
ment of hypertension and CV 
disease [19, 20]. Reduced 
HRV and higher sympathetic 
activity have been consid-
ered strong and independent 
mortality predictors in indi-
viduals with myocardial 
infarction, heart failure, or 
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In humans, the functional importance of the 
Arg16Gly and Gln27Glu β-2 AR polymorphisms 
has been studied in cardiac and vasodilator 
responses. The β-2 AR is responsible for vaso-
dilatation in the vasculature via the cAMP path-
way in smooth muscle cells or through the 
release of nitric oxide (NO) from vascular endo-
thelium [27]. The effect of the β-2 AR genotype 
has been investigated for responsiveness to 
local infusions and systemic infusions of ago-
nists. Evidence has been collected supporting 
the concept that Gly16, and possibly Glu27, is 
associated with greater β-2 AR-agonist-
mediated vasodilatation than Arg16 and Gln27 
[8].
The difference between the responses of local 
infusion studies, which reveal that Gly16 and 
Glu27 homozygotes presents greater vasodila-
tation, and systemic infusion studies, which 
show greater vasodilatation in Arg16 or 
Arg16+Gln27 homozygotes, is probably due to 
the impact of counter-regulatory baroreflex acti-
vation and the compensation for this reflex in 
reason of augmented vasodilatation in Gly16 or 
Glu27 carriers. Once baroreflex inhibition was 
established, raising blood pressure to baseline 
levels, systemic vascular resistance tended to 
come under the influence of haplotype, and it 
was significant at position 16, since Gly16 
homozygotes had a lower systemic vascular 
resistance response to terbutaline than Arg16 
homozygotes [8].
In the heart, β-2 is located in the presynaptic 
terminal sympathetic nerve and in the myocar-
dium. Presynaptic β-2 AR activation stimulates 
cardiac norepinephrine release, and postsyn-
ethnicity, and hemodynamic parameter. More- 
over, Gly16 homozygotes had greater cardiac 
output and stroke volume at rest than Arg16 
homozygotes [29], as well as during low- and 
high-intensity exercises [23].
These studies of cardiovascular function in 
healthy young subjects demonstrated that 
Arg16 allele carriers have attenuated resting 
cardiovascular function. Our results add to this 
information, because we demonstrate a 
reduced baseline heart rate and increased 
baroreflex sensitivity and vagal modulation in 
homozygous carriers of the Arg16 allele. 
However, since blood pressure is a phenotype 
controlled by several other mechanisms, it is 
necessary to consider the link of Arg16Gly poly-
morphism to other systems and environmental 
factors, such as sodium intake and renal sodi-
um excretion, and its impact on blood pressure 
levels [30]. 
In conclusion, the variability of β2-AR function 
resulting from genetic polymorphisms may 
account for the cardiac autonomic modulation, 
in special heart rate variability and baroreflex 
sensitivity in Brazilian health subjects, seen in 
this study. Our results strongly support the 
hypothesis that the Arg16 allele has a protec-
tive effect showed by increased parasympa-
thetic modulation in studied individuals. 
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Var RR (ms) 5738 (±526) 5500 (±544) 5353 (±887) 0.91
LF (ms2) 1296 (±129) 1593 (±321) 1564 (±210) 0.67
HF (ms2) 1272 (±232) 1611 (±145) 1632 (±176) 0.31
LF (%) 50 (±4) 50 (±5) 49 (±4) 0.98
HF (%) 50 (±4) 50 (±5) 51 (±4) 0.98
LF/HF 1.01 (±0.12) 0.99 (±0.11) 0.95 (±0.11) 0.95
Var SAP 51 (±10) 57 (±8) 55 (±11) 0.53
LF (mmHg2) 5± (1.2) 7 (±1) 7 (±1) 0.33
α index (ms/mmHg) 16 (±0.8) 18 (±0.9) 18 (±1.6) 0.30
Values are mean and standard deviation (± SD). P-values=comparison among 
groups.
aptically enhances cardiac 
frequency and contractility 
[2]. 
The β-2 AR genotype may be 
linked to ventricular function. 
In normotensive humans, 
echocardiographic evalua-
tion showed Gly16 homozy-
gotes have greater fractional 
shortening, ejection fraction, 
midwall shortening, and stre- 
ss-corrected midwall short-
ening than either heterozy-
gotes or Arg16 homozygotes 
[28]. These differences were 
independent of various con-
founders, such as age, sex, 
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